Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine CapabilitySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine CapabilityAddressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply WorldwideSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 TrialSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 TrialRepresents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid tumor therapy) and GEO-MVA (Mpox/Smallpox vaccine)
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will review 2024 progress in a presentation at the Biotech Showcase coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025.
David Dodd, CEO of GeoVax Labs Inc. (NASDAQ: GOVX), to Present at NobleCon20In the dynamic field of biotechnology, GeoVax Labs (
NASDAQGOVX) is at the forefront of developing innovative vaccine therapies. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Participate in Upcoming Investor Conferences in SeptemberSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BioMedNewsBreaks — GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional InvestorGeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share as part of a registered direct offering. The company will also issue the investor(s), in a concurrent private placement, warrants to purchase up to 1,700,000 shares of common stock. The exercise price of the warrants is also $5 per share. The warrants will be exercisable immediately following the date of issuance and will expire five years from being issued. Roth Capital Partners is the exclusive placement agent for the offering.
Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Labs CEOSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs.
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the Emerging Growth Conference on August 21, 2024Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory BoardSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee ReviewSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee ReviewSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
